How Much Does Prolia Cost With and Without Insurance?

What Does Prolia Cost Without Insurance?

Without insurance, a single Prolia injection runs approximately $1,600 to $1,900 at most U.S. pharmacies, depending on location and pharmacy markup. The wholesale acquisition cost (WAC) set by Amgen is roughly $1,827 per dose, translating to about $3,654 per year for the standard twice-yearly schedule [1]. That figure does not include the office visit or administration fee, which typically adds $20 to $80 per injection.

The price has risen steadily since the drug's FDA approval in June 2010 for postmenopausal women at high fracture risk [2]. According to an analysis published in the Journal of Bone and Mineral Research, the annual cost of denosumab in the United States was among the highest of all osteoporosis therapies when compared to generic bisphosphonates, which average $48 to $240 per year [3]. Some specialty pharmacies offer modest discounts, but the cash price rarely drops below $1,500 per injection without a copay card or patient assistance program.

Patients paying out of pocket should request a price check at multiple pharmacies. Costco, military pharmacies, and mail-order services sometimes offer lower pricing than retail chains. Prolia is a biologic (not a small-molecule drug), so no FDA-approved biosimilar is currently available in the U.S. market, limiting generic alternatives.

How Much Does Prolia Cost With Insurance?

For patients with commercial insurance, out-of-pocket costs for Prolia typically range from $0 to $150 per injection after the plan's deductible is met. Coverage depends on the insurer's formulary tier and whether the drug is classified under the medical benefit (administered in-office) or the pharmacy benefit (self-injection at home).

Most commercial payers place Prolia on a specialty tier. A 2022 formulary analysis found that approximately 87% of commercial plans covered denosumab, though prior authorization was required by nearly 60% of those plans [4]. Prior authorization criteria usually require documented bone mineral density (BMD) T-scores of -2.5 or lower, a history of fragility fracture, or documented intolerance to oral bisphosphonates.

The Endocrine Society's 2020 clinical practice guideline for postmenopausal osteoporosis states: "Denosumab is recommended as an initial treatment option for postmenopausal women at high fracture risk" [5]. That recommendation strengthens the case for insurance approval when patients meet risk criteria. If your plan denies coverage, ask your provider to submit a peer-to-peer appeal citing the Endocrine Society guideline and your FRAX score.

Medicare Part B Coverage for Prolia

Medicare Part B covers Prolia when a healthcare provider administers it in an office or outpatient setting. This is a significant advantage over oral medications, which fall under Part D. Under Part B, the standard cost-sharing structure applies: 20% coinsurance after the annual Part B deductible ($257 in 2025). That puts the patient's share at roughly $365 per injection, or about $730 per year, before any supplemental insurance kicks in [6].

Medigap (Medicare Supplement) plans often cover the 20% coinsurance entirely, reducing the out-of-pocket cost to $0. Medicare Advantage plans vary. Some charge fixed copays of $40 to $100 per injection; others apply percentage-based coinsurance.

Patients enrolled in Medicare Part D who self-administer Prolia at home face a different cost structure, often with higher copays on the specialty tier. For this reason, most clinicians recommend in-office administration to keep Prolia under Part B.

One common point of confusion: Prolia and Xgeva contain the same molecule (denosumab) but at different doses for different indications. Xgeva (120 mg) is approved for skeletal events in cancer patients. Medicare will deny a Prolia claim if the wrong product code or diagnosis is submitted. Confirm your provider bills under the correct HCPCS code (J0897 for Prolia).

Amgen's Copay Assistance and Patient Programs

Amgen offers two financial assistance programs for Prolia. For commercially insured patients, the Prolia copay card can reduce out-of-pocket costs to $0 per injection, with a maximum benefit of $1,500 per injection. This card is not available to patients covered by Medicare, Medicaid, or other government-funded programs.

For uninsured or underinsured patients, Amgen's Safety Net Foundation provides Prolia at no cost to those who meet income eligibility requirements (generally household income at or below 300% of the federal poverty level). The application requires proof of income and a prescription from a treating physician. Processing time is typically 2 to 4 weeks.

A few practical tips for maximizing savings: enroll in the copay card before your first injection so the card is active at time of billing. If you lose coverage mid-year, contact the Safety Net Foundation immediately, as gaps in denosumab dosing carry clinical risk. As the AACE 2020 guidelines note: "Discontinuation of denosumab results in rapid bone loss and may increase vertebral fracture risk; transition to an alternative antiresorptive agent is recommended" [7].

How Prolia Compares to Other Osteoporosis Drug Costs

The cost difference between Prolia and generic bisphosphonates is stark. Oral alendronate (generic Fosamax) costs $4 to $20 per month at most pharmacies, making it roughly 15 to 75 times cheaper than denosumab on an annual basis [3]. Risedronate (generic Actonel) runs $15 to $45 per month. Intravenous zoledronic acid (Reclast), given once yearly, costs approximately $1,200 to $1,500 per infusion at hospital outpatient rates, still less than Prolia's annual price.

The FREEDOM trial (N=7,868) demonstrated that denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 3 years compared to placebo [8]. These efficacy numbers are broadly comparable to those seen with zoledronic acid in the HORIZON trial, which showed a 70% reduction in vertebral fractures [9]. The cost-effectiveness debate between these two agents is ongoing.

A 2021 cost-effectiveness analysis published in Osteoporosis International found that denosumab was cost-effective compared to no treatment in women aged 70 and older with T-scores of -3.0 or below, but not consistently cost-effective compared to generic alendronate for treatment-naive patients with moderate fracture risk [10]. For patients who cannot tolerate or absorb oral bisphosphonates (those with esophageal disorders, malabsorption, or inability to remain upright for 30 minutes), denosumab becomes the preferred injectable option.

Cost of Evenity Compared to Prolia

Evenity (romosozumab-aqqg) is an anabolic agent approved for postmenopausal women at high fracture risk. It works by a different mechanism, inhibiting sclerostin to stimulate bone formation while simultaneously reducing bone resorption. The cost is substantially higher than Prolia: Evenity's WAC is approximately $2,100 per monthly injection, and the drug is given as two subcutaneous injections per month for 12 months [11]. That puts the total course cost at roughly $25,200 before insurance.

In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fractures by 48% compared to alendronate alone at 24 months [12]. The FRAME trial (N=7,180) showed romosozumab reduced vertebral fractures by 73% versus placebo at 12 months [13]. These results are impressive, but the drug carries a boxed warning for cardiovascular risk. The FDA label states that romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year [11].

Insurance coverage for Evenity is less consistent than for Prolia. Many commercial plans require prior authorization and step therapy (failure of a bisphosphonate first). Medicare Part B covers Evenity when administered in-office, but the 20% coinsurance on a $25,200 course totals over $5,000 before supplemental coverage. Amgen offers a copay assistance program for Evenity that can reduce costs to $0 per month for eligible commercially insured patients.

Insurance Coverage for Anabolic Bone Agents

Anabolic agents for osteoporosis (teriparatide/Forteo, abaloparatide/Tymlos, and romosozumab/Evenity) are the most expensive class of osteoporosis drugs. Forteo costs approximately $3,600 per month at WAC for daily self-injection [14]. Tymlos runs about $2,800 per month [15]. Both are given for a maximum of 2 years.

Insurance approval for anabolic agents typically requires meeting all of the following criteria: a BMD T-score of -2.5 or lower (or -2.0 with additional risk factors), a history of fragility fracture while on antiresorptive therapy, or very high FRAX-calculated fracture probability. Dr. Clifford Rosen, a senior scientist at Maine Medical Center Research Institute and former editor of the Journal of Clinical Endocrinology & Metabolism, has stated: "The cost barrier for anabolic agents remains the single largest obstacle to their broader use in patients who would clearly benefit from bone-forming therapy" [16].

Medicare Part D covers Forteo and Tymlos (self-administered injectables), but specialty-tier copays can reach $500 to $1,000 per month. Medicare Part B covers Evenity (office-administered). Some states have enacted step-therapy reform laws that limit how many drugs a patient must fail before an insurer approves a specialty medication. Check your state's insurance regulations if your plan requires bisphosphonate failure before approving an anabolic agent.

For patients facing high out-of-pocket costs on anabolic agents, manufacturer programs can help. Eli Lilly's Forteo copay card reduces costs for commercially insured patients, and Radius Health (now acquired by Ipsen) offers assistance for Tymlos. These programs do not apply to government-funded insurance.

When Is Prolia Worth the Higher Cost?

The clinical scenarios where Prolia's cost is justified over cheaper alternatives are well defined. The drug is preferred when a patient cannot take oral bisphosphonates due to gastrointestinal disorders, renal impairment (eGFR <35 mL/min, where bisphosphonates are contraindicated), or adherence concerns with daily or weekly pill schedules [5]. Twice-yearly dosing is a genuine advantage. Real-world adherence data show that 12-month persistence with denosumab (approximately 62 to 82%) exceeds that of oral bisphosphonates (approximately 30 to 50%) [17].

Prolia is also the preferred antiresorptive for patients transitioning off anabolic agents. After completing a course of Forteo, Tymlos, or Evenity, patients must consolidate bone gains with an antiresorptive. The ACR/ASBMR guidelines recommend denosumab or a bisphosphonate for this purpose [18]. Denosumab may preserve more of the BMD gained during anabolic therapy compared to oral alendronate, based on data from the DATA-Switch study, which showed continued BMD gains at the spine of 18.3% over 4 years when teriparatide was followed by denosumab [19].

The decision ultimately comes down to fracture risk, drug tolerability, and financial situation. For a 72-year-old woman with a T-score of -3.2, a prior vertebral fracture, and Medicare Part B with Medigap supplemental coverage, her out-of-pocket cost for Prolia may be $0 per year. That same patient paying cash faces a $3,654 annual bill. Both numbers need to be weighed against the cost of a hip fracture, which averages $44 to 600 in acute care and rehabilitation expenses in the first year [20].

How to Reduce Your Prolia Costs

Start by confirming your insurance benefit type. If your plan covers Prolia under the medical benefit (Part B for Medicare, in-office administration for commercial plans), your costs will generally be lower than pharmacy-benefit pricing. Ask your provider's billing staff to verify coverage before your first injection.

Next steps to lower your out-of-pocket spending:

1. Enroll in Amgen's copay card (commercial insurance) or Safety Net Foundation (uninsured/underinsured) before your first dose.
2. If you have Medicare, check whether your Medigap or Medicare Advantage plan covers the 20% Part B coinsurance.
3. Request a predetermination of benefits from your insurer so you know your exact copay before the injection date.
4. Ask about hospital outpatient department pricing versus physician office pricing. Hospital-based clinics sometimes charge facility fees that increase cost-sharing.
5. If switching from Prolia, do not stop without a transition plan. Discuss bridging to a bisphosphonate with your provider to prevent rebound vertebral fractures [7].

Generic denosumab is not yet available in the United States. Amgen's key patents on Prolia extend into the late 2020s, and biosimilar development timelines suggest the earliest U.S. biosimilar entry could occur around 2028 to 2030. Until then, financial assistance programs and insurance optimization remain the primary tools for cost reduction.

The average Medicare Part B reimbursement rate for a single Prolia injection (including administration) was $1 to 893.42 in Q1 2025 [6].